biostudies-literatureAndersen JNational Health Medical Research Council (AustraliaMS AustraliaSydney Research Excellence Initiative 2020109-119https://www.ebi.ac.uk/biostudies/studies/S-EPMC12911599biostudies-literatureUnknown97(2)<h4>Background</h4>Detection of immunoglobulin G targeting myelin oligodendrocyte glycoprotein (MOG-IgG) is the mainstay of laboratory diagnosis of MOG antibody-associated disease. Laboratory biomarkers have the potential to predict disease course and activity, thus informing prompt therapeutic decisions to minimise relapse-associated disability accrual.<h4>Methods</h4>This systematic review with meta-analysis was registered in PROSPERO (CRD42024554429). MEDLINE, Embase and Scopus databases were searched. Random-effects or mixed-effects modelling was performed and OR or HR with 95% CIs reported.<h4>Results</h4>106 studies with ≥1710 individuals were included. A relapsing course was associated with persistent seropositivity on serial samples collected ≥3 months apart (OR 2.7 (95% CI 1.8 to Journal of neurology, neurosurgery, and psychiatryBiomarkers to predict relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: a systematic review and meta-analysis.PMC12911599RCD GNT1193648N/AFB GNT2016841SR GNT2008339Trewin BPRamanathan SDale RCAndersen JBrilot FfalseBiomarkers to predict relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: a systematic review and meta-analysis.<h4>Background</h4>Detection of immunoglobulin G targeting myelin oligodendrocyte glycoprotein (MOG-IgG) is the mainstay of laboratory diagnosis of MOG antibody-associated disease. Laboratory biomarkers have the potential to predict disease course and activity, thus informing prompt therapeutic decisions to minimise relapse-associated disability accrual.<h4>Methods</h4>This systematic review with meta-analysis was registered in PROSPERO (CRD42024554429). MEDLINE, Embase and Scopus databases were searched. Random-effects or mixed-effects modelling was performed and OR or HR with 95% CIs reported.<h4>Results</h4>106 studies with ≥1710 individuals were included. A relapsing course was associated with persistent seropositivity on serial samples collected ≥3 months apart (OR 2.7 (95% CI 1.8 to 2026-01-01T00:00:00Z2026 Jan2026-07-16T00:42:03.271Z2026-07-09T10:26:11.047ZS-EPMC129115994103378410.1136/jnnp-2025-337039